Form 4: Apellis Director O'Brien Receives Equity Grants

Apellis Pharmaceuticals director Stephanie Monaghan O'Brien was granted 7,961 restricted stock units and 14,684 stock options effective January 1, 2026.

Summary

• Director Stephanie Monaghan O'Brien of Apellis Pharmaceuticals, Inc. (APLS) was granted equity awards.
• On January 1, 2026, O'Brien received 7,961 restricted stock units (RSUs) at a price of $0.
• These RSUs will fully vest on January 1, 2027, subject to her continued service as a director or upon later termination of service at her election.
• Additionally, on January 1, 2026, O'Brien was granted 14,684 stock options with an exercise price of $25.12.
• These stock options will vest quarterly on the last day of each quarter from the grant date, subject to her continued service as a director.
• The stock options are reported to expire on December 31, 2033.
• Following these transactions, O'Brien beneficially owns 25,666 shares of common stock and 14,684 stock options directly.

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to a director, which is a positive for aligning management incentives but generally neutral for the company's immediate stock price. It reflects standard compensation practices.

Positives

• Director Stephanie Monaghan O'Brien received a grant of 7,961 restricted stock units, aligning her interests with long-term shareholder value.
• Director O'Brien also received a grant of 14,684 stock options, providing an incentive for future performance and stock price appreciation.

Future Outlook

The 7,961 restricted stock units are scheduled to fully vest on January 1, 2027, contingent on continued service as a director. The 14,684 stock options, granted on January 1, 2026, will vest quarterly on the last day of each quarter from the grant date, subject to continued service, and are reported to expire on December 31, 2033.

Industry Context

This filing represents routine director compensation, a common practice across the pharmaceutical industry to align executive and director incentives with long-term company performance and shareholder interests.

Related Party Transactions

• The equity grants to Director Stephanie Monaghan O'Brien represent compensation from Apellis Pharmaceuticals, Inc., which is a related party transaction as she is a member of the board.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by incentivizing long-term stock performance.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The 7,961 restricted stock units will fully vest on January 1, 2027.
• The 14,684 stock options will vest quarterly on the last day of each quarter from January 1, 2026.
• Continued service as a director is required for vesting of both equity awards.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Stephanie Monaghan O'Brien, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Form 4